(509) 228-1000 WA
(208) 754-3100 ID

Clinical Research

TRIAL NUMBER - NCT05899608

Cancer Type: Lung

Lead Physician: Jessica Hellyer

This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoint is overall survival and key secondary endpoints include progression free survival. response and safety.

 

I Want to Participate

Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician. 

View Trial

For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:

  • Your name
  • Phone number & if we can leave a voice message at this number
  • Trial number(s) you are interested in
  • Name and city of clinic you are currently being treated